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Mechanism of erythrocyte accumulation of methylation inhibitor S-
adenosyihomocysteine in uremia. We have recently demonstrated that
methyl esterification of erythrocyte membrane proteins, a reaction in-
volved in recognition and repair of specifically damaged proteins, is
impaired in uremia. This is accompanied by a significant increase in
intracellular S-adenosylhomocysteine (AdoHcy), a potent inhibitor of
methyltransferases. AdoFicy accumulation is normally prevented by its
enzymatic hydrolysis to homocysteine (Hey) and adenosine, a reversible
reaction catalyzed by AdoHcy hydrolase. To assess the contribution that
Hey offers in the elevation of AdoHcy, we measured plasma and red blood
cell Hey, AdoHcy, adenosine, and S-adenosylmethionine (AdoMet) intra-
cellular concentrations, as well as RBC AdoHcy hydrolase specific activity,
in standard hemodialysis patients and normal subjects. Plasma and red
blood cell Hey levels are significantly higher in the dialysis group, and are
positively correlated to AdoHey levels. Adenosine and AdoMet levels, and
AdoHey hydrolase specific activity are not significantly different between
the two groups. The enzymatic formation of labeled AdoHey from Hey
and tracer adenosine appears to be significantly increased, in vitro, in
erythrocytes from both control and uremic patients, when 50 M Hey
(concentration comparable to plasma levels actually found in vivo in
uremic patients) is added to the incubation medium. When eiythrocytes
from uremic patients are incubated in Vitro in absence of Hey, a significant
reduction of intracellular AdoHey is observed with time compared to
identical samples incubated in presence of 50 j.M Hey, with a T112 of
approximately 270 minutes. The results allow us to conclude that plasma
and red cell Hey levels actually found in uremia can be effectively
responsible for the intracellular accumulation of the toxic compound
AdoHey.
We have demonstrated that carboxyl methyl esterification of
erythrocyte membrane proteins is impaired in chronic renal
failure (CRF) patients treated conservatively, or on hemodialysis
therapy [1]. This enzymatic reaction is involved in the recognition
and repair of specific protein damages induced by spontaneous
deamidation, racemization and isomerization reactions at the
level of asparaginyl and aspartyl residues [2—8]. Decrease in
enzymatic protein methylation in uremia is accompanied by a
significant increase in the intracellular concentration of S-adeno-
sylhomocysteine (AdoHcy) [1], a potent competitive inhibitor of
most, if not all, methyltransferases [9—121. No change in S-
adenosylmethionine (AdoMet) concentration was noted; thus, the
Received for publication April 18, 1994
and in revised form August 5, 1994
Accepted for publication August 12, 1994
© 1995 by the International Society of Nephrology
resulting inhibitory effect of the altered [AdoMet]/[AdoHcy] ratio
brings about the observed reduction in membrane protein car-
boxyl methyl esterification. However, the mechanisms responsible
for this elevation in AdoHcy and the consequent change in
[AdoMet]/[AdoHcy] ratio have not yet been elucidated.
The intracellular concentration of AdoHcy is normally main-
tained at low levels through its enzymatic hydrolysis, catalyzed by
AdoHcy hydrolase (E.C. 3.3.1.1) [9, 10, 13]. However, AdoHcy
breakdown to its hydrolysis products adenosine and homocysteine
(Hey) is a readily reversible reaction [11]:
Adenosine + Hey AdoHcy
It has been shown that the reaction in vivo proceeds in the
direction of hydrolysis since the products are rapidly removed,
while in vitro thermodynamics actually favor synthesis of AdoHcy
[9, 101.
It is well known that plasma Hey is significantly increased in
uremic patients [14—18], and it has been reported that it is able to
cross the cellular membrane barrier [11]. Such a process would
induce an increase of erythrocyte Hey, and this in turn would favor
AdoHcy production, and therefore be responsible of the accumu-
lation of AdoHcy in uremia. An inhibition of Adollcy hydrolysis
in uremia could also cause an elevation in AdoHcy. The present
investigation examined the mechanism responsible for the intra-
cellular elevation of AdoHcy in uremic patients, with the aim to
elucidate if plasma levels of Hey in the range observed in uremia
can bring about an increase of erythrocyte AdoHcy.
Methods
Patients
Two groups of subjects were studied: (1) a control group of
healthy individuals age and sex matched with patients of group 2;
(2) patients on standard bicarbonate hemodialysis therapy thrice
weekly, clinically stable at the time of investigation, age range 38
to 62 (mean 50 3), treated with erythropoietin i.v. to reach a
30% hematocrit. This group in particular was selected because
our previous work [1] showed that hemodialysis patients with no
residual renal function displayed consistently high levels of eryth-
rocyte AdoHcy and reduced membrane protein methyl esterifica-
tion. Causes of renal failure were chronic glomerulonephritis,
chronic obstructive nephropathy, or polycystic renal disease.
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Blood pressure and phosphate levels were kept under pharmaco-
logical control. Patients with systemic pathologies (hypertension,
cardiac disease, diabetes mellitus, vasculitis) who were under
treatment with inhibitors of cyclic nucleotide phosphodiesterases
[19] were excluded from the study. Selected patients stopped
vitamin or folate supplementation for at least three months prior
to the study. All patients gave informed consent.
On the day of the study, routine biochemical tests (Hitachi 911
Automatic Analyzer) and blood cell count, were performed. In
the dialysis group, blood was drawn immediately before the
dialysis session. Blood samples were collected in the fasting state
by venipuncture, using EDTA (1 mg/mI of blood).
S-adenosyl-L-[methyl-3H]methionine (sp act 80 Ci/mmol) and
[8-'4C]adenosine (sp act 46 mCi/mmol) were obtained from
Amersham International, UK. D,L-Homocysteine was from Sigma
Chemical Co. (St. Louis, Missouri, USA). Leibovitz L-15 modified
cell medium was from ICN Biomedicals (Milan, Italy).
HPLC determination of plasma and eythrocyte Hcy
Determination of total Hcy in plasma and red blood cells
(RBCs) was carried out according to the method of Ubbink et al
[20], with some modifications. Whole blood was centrifuged and
deprived of leukocytes and platelets, as described by Galletti et al
[211, with further modifications [22]. Erythrocytes were processed
along with plasma samples without any previous washings to
prevent Hcy leakage from the intracellular space. Thirty micro-
liters of a 10% solution of tri-n-butil-phosphine in dimethylform-
amide (vol/vol) were added to 0.27 ml of fresh plasma, 0.3 ml fresh
packed RBCs, or Hcy standard. The mixture was incubated at 4°C
for 30 minutes to obtain reduction of homocystine and the mixed
disulfide cysteine-Hcy, and the release of protein-bound Hcy.
Subsequently, 0.3 ml of a 10% trichloroacetic acid solution
containing 1 mM EDTA, was added. After centrifuging for 10
minutes at 10000 X g, 100 pJ of the supernatant were added to 20
1.d of 1.55 M NaOH, 250 j.il of 0.125 M borate buffer, pH 9.5,
containing 4 mM EDTA, and 100 1.d of ammonium 7-fluorobenzo-
2-oxa-1,3-diazole-4-sulphonate (SBD-F, a thiol specific fluoro-
genic probe) solution, dissolved in borate buffer (1 mg/ml). The
mixture was vortexed and incubated for one hour at 60°C to reach
complete derivatization of thiols, with consequent formation of
fluorescent products. Fifty microliters for plasma or 200 d for
RBC sample aliquots were utilized for isocratic HPLC analysis. A
Beckman pump system Model 100A (Beckman Instruments, San
Ramon, California, USA) was fitted with a Supelco (Bellefonte,
Pennsylvania, USA) LC-18-DB analytical column (150 mm X 4.6
mm I.D.) provided with a Supelguard pre-column. Fluorescence
intensities were measured with excitation at 385 nm and emission
at 515 nm, using a Shimadzu RF-535 fluorescence detector
(Shimadzu Co., Kyoto, Japan) equipped with a Shimadzu Chro-
matopac C-R6A data processor. Detection conditions were opti-
mized for Hcy. The mobile phase was 0.1 M KH2PO4, pH 2.1,
containing 4% acetonitrile (ACN), with a flow rate of 2.0 ml/min.
Retention time of Hcy was four minutes, and recovery, assessed
by running samples containing an Hcy internal standard, was
complete. Micromolar concentrations of Hcy are referred to 1
liter of packed erythrocytes, or to 1 liter of whole plasma.
HPLC determination of intracellular AdoHcy, AdoMet and
adenosine
Erythrocytes were processed as previously described [1], and
stored at —80°C for later use. In preparation for HPLC analysis,
frozen packed red cells were thawed, processed and analyzed as
outlined earlier [1]. Retention times were 13 minutes for adeno-
sine, 15.1 minutes for AdoHcy, and 17.2 minutes for AdoMet.
Micromolar concentrations of the indicated compounds are re-
ferred to 1 liter of packed erythrocytes.
Determination of AdoHcy hydrolase activity
AdoHcy hydrolase specific activity was determined with a
radioenzymatic method coupled to HPLC analysis, by measuring
the formation of AdoHcy from [8-'4C]adenosine and Hcy, accord-
ing to the method of Kaminska and Fox [23], Hershfield et al [24],
and Chiang [25], with modifications. Packed RBCs stored at
—80°C were thawed and either immediately diluted 1:19 in 10 mrvi
KH2PO4, pH 7.4, or diafiltrated prior to dilution. Diafiltration was
performed against 20 volumes of 1 m'vi Tris-HC1, pH 7.4, and 0.1
mM EDTA buffer, at 4°C, utilizing Centricon-30 Amicon mi-
croconcentrators, and repeated twice. The incubation medium
contained in a final volume of 50 il, 20 1.il of diluted hemolysate,
25 mM KH2PO4, 1 m'vi dithiothreitol, 1 mi Na2-EDTA, 5 LM
erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA), 10 mM Hcy, and
161 M Ado. EHNA, an adenosine deaminase inhibitor, was
added to prevent adenosine hydrolysis. The mixture was incu-
bated for 20 minutes at 37°C, and the reaction stopped by the
addition of 50 jtl of 20% perchloric acid. After centrifuging for
five minutes at 4000 rpm, the clear supernatant was processed in
the same system described above. Radioactivity of the AdoHcy
peak was collected and counted with a Beckman liquid scintilla-
tion spectrometer, model LS 7800. Results are expressed as
nmol/hr/mg hemoglobin (Hb). Hb concentration was determined
by measuring ultraviolet absorbance at 280 nm wavelength, as
previously reported [1].
Glutamic oxalacetic transaminase (GOT) activity
GOT (E.C. 2.6.1.1) specific activity in erythrocyte cytosol was
measured at 37°C, on the diluted hemolyzed samples utilized for
AdoHcy hydrolase assay, obtained as follows: erythrocyte samples
were diluted 1:9 with a stabilizing solution, consisting of 2.7 mM
EDTA, pH 7.0, and 0.7 mrvt 13-mercaptoethanol, followed by rapid
freeze-thawing, according to Beutler [26]. The assay method
described by Beutler was employed, and results expressed as U/g
Hb (tmol of substrate converted/min/g Hb).
In vitro experiments
Fresh RBCs, isolated from control subjects or from uremic
patients, where incubated in vitro under either condition A or B
[modified from 111.
Condition A (short incubation). Fresh packed RBCs from
control and hemodialysis patients were incubated for five minutes
with and without 50 jsM Hcy (a concentration comparable to that
found in the plasma of uremic patients), and a tracer amount (1.3
X iO cpm/ml cell suspension) of [8-14C]adenosine, plus 5 M
EHNA, at a 28% hematocrit. After centrifuging to eliminate the
supernatant, packed red cells were analyzed for AdoHcy as
described above, and radioactivity of the AdoHcy peak was
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Table 1. RBC AdoHcy, AdoMet micromolar concentrations, and
AdoHcy hydrolase specific activity, expressed as nmol/h/mg Hb
Controls Uremic patients
AdoHcy p.M 0.77 0.086 (N=8) 6.67 1.309a (N=15)
AdoMet p.M 2.68 0.293 (N=8) 2.69 0.267 (N 15)
AdoHcy Hydr Diafiltr 5.71 0.506 6.99 0.921
(N = 10)
Nondiafiltr 5.81 0.229 5.96 0.562
(N— 10)
Abbreviations are: AdoHcy Hydr; AdoHcy hydrolase specific activity;
Diafiltr, Diafiltrated samples; Nondiafiltr, nondiafiltrated samples.
AdoHcy and AdoMet concentrations were determined as previously
described [1]. Micromolar concentrations of AdoHcy and AdoMet are
referred to 1 liter of packed erythrocytes. AdoHcy hydrolase specific
activity was determined with a radioenzymatic method coupled to HPLC
analysis, by measuring the formation of AdoHcy from [8-'4C]adenosine
and Hcy, according to the method of Kaminska et al [23], Hershfield et al
[241, and Chiang [25], with modifications.
P < 0.005 vs. control subjects
Fig. 1. Eythrocyte Hcy and adenosine concentrations. Determination of
total Hey in RBCs was carried out according to the method of Ubbink et
a! [20], with some modifications. Detection conditions were optimized for
Hey. Retention time of Hey was 4 minutes, and recovery, assessed by
addition of Hey to samples, was complete. Adenosine RBC concentration
was determined by HPLC analysis, as described under Methods. * J
0.001. Ado = adenosine. Symbols are: (En) control; (U) uremic.
collected and counted with a Beckman liquid scintillation spec-
trometer, model LS 7800.
Condition B (longer incubation). Cells from hemodialysis pa-
tients were rapidly diluted at a 10% hematocrit in the Leibovitz
L-15 modified cell medium. Hey, at a 50 p.M concentration in the
medium, was added, while the control was represented by cells
incubated in the absence of Hey. Cells were then incubated at
37°C for the indicated time in a shaking water bath. Cell aliquots
were taken at definite times (0, 60, 120, 200, and 300 mm),
centrifuged to eliminate the supernatant, and AdoHcy concentra-
tion determined by HPLC as above described. In the in vitro
experiments, hematocrit of sample aliquots was checked by means
of centrifugation to ensure homogeneity among the various
samples processed.
Statistical analysis
Statistical analysis was performed employing Student's un-
paired t-test. Linear regression analysis was done to assess the
independent effects of the different variables [27]. All calculations
were performed using the software package StatWorks (Cricket
Software, Inc., Philadelphia, Pennsylvania, USA), running on an
Apple Macintosh IIfx personal computer. All results are pre-
sented as the mean SEM.
Results
Plasma and eiythrocyte Hey concentration, RBC AdoHcy,
AdoMet, and adenosine levels
Plasma levels of Hey in the control group are 11.78 1.328 p.M
(N = 11); while in the patient group are 40.56 6.884 p.M (N =
17), a concentration significantly higher than the control, with P <
0.003. Results referring to RBC Hcy and adenosine levels are
shown in Figure 1 (RBC Hey: Control N = 11, Hemodialysis N
17; adenosine: Control N = 8, Hemodialysis N = 15). RBC
concentrations of Hey were significantly higher in the hemodi-
alysis group compared to control. Interestingly, plasma levels were
higher than RBC levels, a gradient which was detectable in both
control and patient groups. A good linear correlation was present
between plasma Hey levels and red cell Hey determined on the
same blood samples (r = 0.740, P < 0.01). Adenosine levels in
uremic patients were not significantly different from control.
AdoHcy levels were significantly higher in uremic patients
compared to control, while AdoMet did not differ significantly
from normal subjects (Table 1). Since AdoHcy inhibitory mech-
anism is competitive with respect to AdoMet, it is the relative
concentrations of the two compounds, expressed as concentration
ratio, that will determine the extent of methylation inhibition [9,
11, 28, 29]. The calculated [AdoMet]/[AdoHcy] ratio is signifi-
cantly reduced in the dialysis group (Control 3.57 0.381,
Dialysis 0.78 0.205, P < 0.001), which is in agreement with the
concept that the intracellular microenvironment present in these
patients is not suitable for correct methyl esterification [1].
To evaluate the correlation between plasma Hey and red cell
AdoHcy, the concentrations relative to the indicated compounds
were determined in identical blood samples and plotted. Figure 2
shows that a significant positive correlation between plasma Hey
and red cell AdoHcy is present (r = 0.710, P < 0.001). Similarly,
a significant correlation between RBC Hey and AdoHcy (r
0.706, P < 0.01) was found.
AdoHcy hydrolase activity
The results of AdoHcy hydrolase specific activity are shown in
Table 1, indicating that no significant difference was present in
AdoHcy hydrolase activity between healthy control patients and
uremic patients. No significant difference was also noted when the
enzymatic assays were performed using diafiltrated samples as
enzyme sources. Diafiltration was meant to deplete erythrocytes
of inhibiting compounds possibly present in the samples, and/or of
endogenous substrates.
It has been reported that AdoHcy hydrolase activity in younger
erythrocytes is higher than older erythrocytes [23]. Since it is well
known that in uremia red cell age can be shorter than average
[301, due to increased hemolysis and red cell fragility [31, 32], we
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Fig. 2. Co,relation between plasma Hcy and AdoHcy. AdoHcy RBC con-
centration was determined by HPLC analysis, as previously described [1].
Micromolar concentrations of the indicated compounds are referred to
1 liter of packed eiythrocytes. A scatter plot of Hey values (sM), in the
abscissa, relative to the respective AdoHcy levels (jIM), in the ordinate, is
shown. Open symbols represent control, while closed squares represent
hemodialysis patients. A positive simple correlation between plasma Hey
and AdoHcy concentrations, r 0.71, P < 0.001, is documented.
measured GOT activity as a marker of red cell age [331, in order
to check if enzyme activity correlated with RBC life span. No
significant correlation was found between AdoHcy hydrolase
activity and GOT (data not shown), and there was no significant
difference in GOT activity (Control 5.03 0.29, Hemodialysis
5.66 0.40 U/g Hb, P = NS).
Hey effects on AdoHcy biosynthesis and intracellular accumulation
in vitro
To verify the ability of Hcy to induce and subsequently maintain
high AdoHcy intracellular levels at a concentration equal to that
present chronically in hemodialysis patients, the following exper-
iments were performed.
To put in evidence the possible formation of AdoHcy from Hcy
under conditions similar to those of dialysis patients, we treated
RBCs from control and hemodialysis patients under condition A,
characterized by the presence of tracer amounts of labeled
adenosine in the medium (Methods). In this experiment parallel
samples were incubated in vitro with or without 50 tM Hcy. The
concentration of this compound was chosen on the basis of plasma
concentrations we actually found in vivo in hemodialysis patients.
Results in Figure 3 show a marked rise in radioactive AdoHcy
only in the set of samples incubated with Hey, both in the control,
and in the hemodialysis patient group.
A time course experiment was performed by incubating pooled
RBCs from hemodialysis patients under condition B (Methods).
Erythrocyte samples from hemodialysis patients were incubated
either in the presence or in the absence of 50 j.LM Hey. Aliquots
were taken at 0, 60, 120, 200 and 300 minutes, centrifuged, and the
packed RBCs thus obtained were processed for AdoHcy HPLC
assay. Results are shown in Figure 4. AdoHcy concentrations in
Fig. 3. AdoHcy formation in RBCs of control and hemodialysis patients in
vitro. RBCs from control and hemodialysis patients were shortly incubated
in vitro under condition A (Methods), with [8)4C]adenosine, either in the
presence (•) or in the absence () of 50 M Hey. At the end of the
treatment cells were rapidly processed, AdoHcy isolated by HPLC, and
radioactivity coeluting with AdoHcy was measured by liquid scintillation
counting. The hematocrit of sample aliquots was checked by means of
centrifugation to ensure homogeneity among the various samples pro-
cessed, and found to be not different from 26% in all samples. Error bars
show the range of triplicate measurements. Condition A produced a
marked rise in incorporated radioactivity measured as AdoHcy only in the
set of samples incubated with Hey.
the samples incubated in the absence of Hey were expressed, at
each time point, as percentage of the corresponding values
observed in identical samples incubated in the presence of Hey. It
can be noted that a time dependent decrease of intracellular
AdoHcy took place when Hey was removed from the medium,
with a t112 of approximately 270 minutes.
Discussion
The present study shows that both plasma and RBC Hey levels
are significantly higher in uremic patients undergoing hemodial-
ysis therapy, with respect to normal healthy controls. Hey, which
is known to easily cross the red cell membrane [11], builds up in
red cells, and the actual RBC levels found in uremic patients are
almost four times higher than normal cells. A significant correla-
tion between plasma Hey levels and red cell Hey is present.
Conversely, adenosine content is not different between the two
groups, indicating that this compound plays no apparent role in
the elevation of intracellular AdoHcy detected in vivo in hemo-
dialysis patients.
Furthermore, the levels of red blood cell AdoHcy, which are
shown to be increased in these patients compared to control,
correlate significantly with both plasma and intracellular Hey.
Specific activity of AdoHcy hydrolase is not significantly differ-
ent compared to control, either in the extensively diafiltrated or in
the nondiafiltrated samples. Diafiltration was performed in order
to reduce the impact of any possible inhibitory substance on this
enzyme, or the effects of endogenous substrates.
In the end, our data do not support the view that the accumu-
lation of AdoHcy is caused by a decreased enzyme function in
hemodialysis patients.
The in vitro experiments that involve the use of concentrations
of Hey in the range present in uremic plasma (Fig. 3), thus closely
resembling an in vivo situation, demonstrate that, in RBCs from
control and from hemodialysis patients incubated with tracer
.
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requiring maintenance hemodialysis therapy, but on the contrary
it is enhanced [1]. Furthermore, the intracellular ratio [AdoMet]/
[AdoHcy], an indicator of the inhibition potential of AdoHcy on
AdoMet-dependent enzymatic reactions, decreases 5- to 10-fold
in the patient population [1].
Type II MTase (D-aspartyllL-isoaspartyl protein carboxyl
methyltransferase, E.C. 2.1.1.77) is an ubiquitous enzyme impli-
cated in the repair of specific structural damages, due to aspar-
aginyl deamidation and aspartyl isomerization mechanisms spon-
taneously occurring in proteins [3, 35—40], and leading to less
active or potentially toxic protein derivatives [7, 8, 39]. A signifi-
cant decrease in erythrocyte membrane protein methyl esterifica-
tion, catalyzed by Type II MTase, accompanied the noted increase
in AdoHcy [1]. In particular, the reduction was significant for
band 2.1 [1], a cytoskeletal component involved in membrane
stability and integrity [41]. In the end, it appears that damaged
membrane proteins accumulate in CRF and are not adequately
repaired, and that this is due to the high levels of AdoHcy present.
0 50 100 150 200 250 300 The results presented in this paper allow us to trace the
abnormal build up of the inhibitor AdoHey to the abnormal
elevation of Hcy occurring in these patients.
The intracellular accumulation of AdoHcy is normally pre-
vented by the action of the enzyme AdoHcy hydrolase, which
catalyzes the reversible hydrolysis of AdoHcy to adenosine and
Hey [9, 10, 12, 29]. As a result, under normal conditions (that is,
low Hey present), transmethylation reactions are not likely to be
affected by AdoHcy [9, 10]. The equilibrium constant for AdoHcy
hydrolysis is highly unfavorable, so Hey must be further metabo-
lized, along with adenosine, in order to insure AdoHcy cleavage,
and prevent its accumulation. On the other hand, Hey can be
converted to AdoHcy, if in excess, through the action of the same
enzyme.
Hyperhomocysteinemia is a common feature in CRF patients,
either treated conservatively or necessitating dialysis. It has been
reported for the latter group a three- to fourfold increase of Hey
[14—16], which is in agreement with our present findings.
According to Laidlaw et al [15], elevated plasma Hey can only
be partially lowered during a hemodialysis session. High plasma
Hey can be a consequence of decreased renal excretion caused by
nephron loss, decreased metabolism to cystathionine, or to im-
paired remethylation to methionine, due to relative folic acid
deficiency [17, 18].
It is widely acknowledged that elevated plasma Hey is an
independent risk factor for occlusive arterial disease, and it is
significantly more common in asymptomatic adults with carotid
artery wall thickening, in a recent case-control study [42, 43].
Since chronic uremic patients exhibit a higher incidence of
cardiovascular disease, high plasma Hey is regarded among the
risk factors that play a role in the genesis of premature athero-
sclerosis in these patients [16, 17].
In our opinion, the information provided in this work broadens
the scope of studies concerning the effects of moderately high
Hey in blood. Actually, it appears that a conspicuous increase of
Hey is not needed in the high micromolar or millimolar range
for Hey to exert detectable biological effects, but even a modest
increase, such as it is present in hemodialysis patients, can
determine tangible in vivo effects that can be quantified. This last
notation requires some comment. Published experiments on Hey
biological and pathological effects are often designed to evaluate
possible actions of Hey present in high plasma concentrations
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Fig. 4. Time dependent Hey effects on RBCAdoHcy content of hemodialysis
patients in vitro. RBCs from hemodialysis patients were incubated in vitro
under condition B, as detailed under Methods, either in the absence, or in
the presence of 50 ItM Hey, a concentration comparable to what actually
found in vivo in hemodialysis patients' plasma. At the indicated time
points cell aliquots were withdrawn and intracellular AdoHcy determined
by means of HPLC. AdoHcy concentrations in the RBCs incubated with
Hey were always significantly lower than those found in the corresponding
samples incubated in parallel in the presence of Hey. Results are
expressed as percentage of AdoHcy content measured in the "minus Hey"
sample, compared to the value measured in the "plus Hey" sample. Error
bars show the range of triplicate measurements. Initial intracellular
AdoHcy was 7.6 0.3 jIM. The hematocrit of sample aliquots was checked
by means of centrifugation to ensure homogeneity among the various
samples processed, and found to be not different from 9% in all samples.
radioactive adenosine and 50 rM Hey, increased Hey can induce
net formation of AdoHey intracellularly.
Moreover, the time course experiment shows that when eryth-
rocytes from hemodialysis patients are kept in an environment
where Hey is absent, the AdoHcy intracellular concentration falls
with time, if compared with the set of RBCs that were incubated
with Hey.
The latter experiment substantiates the view that even in an
environment of chronic exposure to high Hey, such as uremia, the
intracellular accumulation of this compound and its effects can be
at least partially reversed by effective removal of the extracellular
compound. In this respect it should be pointed out that Wilcken
and coworkers [171 reported a significant decrease of plasma Hey
in dialysis patients treated with folic acid as co-factor in the
enzymatic conversion of Hey to methionine.
AdoMet is the universal methyl donor of enzymatic methylation
reactions [34]; thus it is involved in the biosynthesis, modification,
or regulation of the function of phospholipids, proteins, nucleic
acids, small molecules, etc. AdoHcy, the demethylated product of
AdoMet, is a natural inhibitor of all these metabolic processes
[9—12, 28, 29].
We have demonstrated that in CRF a significant increase of
RBC AdoHcy is present, while AdoMet concentration is not
different from control [1]. This pattern is not modified in patients
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specifically as it is found in a condition such as homocystinuria
[44—46]. Untreated patients with homocystinuria usually have
fasting Hcy levels of 0.2 mM; their non fasting levels may be higher
[46].
In summary, this study supports the proposal that accumulation
of AdoHcy is due to the rise in Hcy levels present in these
patients. First, plasma and erythrocyte levels of Hcy correlate with
AdoHcy intracellular levels. Second, control cells incubated with
Hcy present at levels comparable to those of uremic subjects show
a net formation of AdoHcy. Third, red cells from hemodialysis
patients when incubated with Hcy give way to a rise in intracel-
lular AdoHcy, like control subjects. Fourth, the absence of Hcy
from the incubation medium induces a time dependent decrease
in erythrocyte AdoHcy. Fifth, the enzyme AdoHcy hydrolase
specific activity is normal. Moreover, no difference was found in
the intracellular concentration of adenosine in RBCs of hemodi-
alysis patients compared to control, indicating that in vivo the
increase in AdoHcy concentration is solely due to Hcy accumu-
lation.
In conclusion, our results suggest that in uremia AdoHcy
represents a preferential deposit form of Hcy in the intracellular
compartment, at least in erythrocytes. Consequently, AdoHcy can
be considered a prospective highly toxic metabolite of Hcy, since
it is able to interfere with many AdoMet-dependent pathways
involved in the regulation of crucial cell functions [47—53].
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